Champions Oncology (NASDAQ:CSBR) Releases Earnings Results

Posted by George Bondi on Sep 10th, 2026

Champions Oncology (NASDAQ:CSBR – Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.02), Zacks reports. Champions Oncology had a negative net margin of 1.87% and a negative return on equity of 27.48%.

Champions Oncology Trading Up 0.5%

NASDAQ:CSBR traded up $0.03 during mid-day trading on Thursday, hitting $5.04. 11,336 shares of the company’s stock were exchanged, compared to its average volume of 8,364. Champions Oncology has a fifty-two week low of $4.83 and a fifty-two week high of $8.74. The firm has a market capitalization of $70.09 million, a P/E ratio of -62.94 and a beta of 0.40. The company has a 50 day simple moving average of $5.44 and a 200-day simple moving average of $5.82.

Hedge Funds Weigh In On Champions Oncology

A number of hedge funds have recently modified their holdings of CSBR. Mink Brook Asset Management LLC acquired a new stake in Champions Oncology in the fourth quarter valued at $555,000. Essex Investment Management Co. LLC acquired a new position in Champions Oncology during the 4th quarter worth about $126,000. Vanguard Group Inc. grew its position in shares of Champions Oncology by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock valued at $2,158,000 after buying an additional 6,229 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Champions Oncology in the second quarter valued at about $103,000. Finally, Acadian Asset Management LLC increased its stake in shares of Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 8,814 shares during the period. Institutional investors and hedge funds own 41.30% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Get Our Latest Analysis on Champions Oncology

About Champions Oncology

(Get Free Report)

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.